Novel therapeutics targeting telomerase and telomeres

Journal of Cancer Science and Therapy

Volumn 5, Issue 10, 2013, Pages 1-3

  Puri, Neelu ^a   Girard, Jennifer ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIBR 1532; CAPECITABINE; GEMCITABINE; IMETELSTAT; PACLITAXEL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TANKYRASE; TELOMERASE INHIBITOR; TERTOMOTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ASCARIASIS; BREAST CANCER; DNA DAMAGE; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); NEOPLASM; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SAFETY; SOLID TUMOR; SURVIVAL; TELOMERE; THROMBOCYTHEMIA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 84889673538     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000e127     Document Type: Editorial

References (22)

1. Röth A, Harley CB, Baerlocher GM (2010) Imetelstat (GRN163L)--telomerase-based cancer therapy. Recent Results Cancer Res 184: 221-234.
2. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, et al. (2002) Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277: 15566-15572.
3. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, et al. (2005) Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105: 1742-1749.
4. Ward RJ, Autexier C (2005) Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 68: 779-786.
5. Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012) Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 1: 670-686.
6. Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, et al. (2012) Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann Oncol 23: 442-449.
7. Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, et al. (2013) A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 14: 461-465.
8. DiPersio J (2007) A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML).
9. Harley CB (2008) Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179.
10. Xu Y (2011) Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. Chem Soc Rev 40: 2719-2740.
11. Yaar M, Eller MS, Panova I, Kubera J, Wee LH, et al. (2007) Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res 9: R13.
12. Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrest BA (2002) Induction of apoptosis by telomere 3' overhang-specific DNA. Exp Cell Res 276: 185-193.
13. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, et al. (2009) Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer 124: 473-482.
14. Pitman RT, Wojdyla L, Puri N (2013) Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget 4: 761-771.
15. Ruden M, Puri N (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39: 444-456.
16. Fouladi M (2013) Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors.
17. Chiappori A, Kolevska T, Burington B, Spiegel DR, Hager S, et al. (2013) A randomized Phase II STudy of the Telomerase Inhibitor Imetelstat as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer. Annual Meeting 2013, Washington, DC.
18. Chiappori A, Bassett K, Burington B, Spiegel DR, Hager S, et al. (2013) Improved Progression Free Survival (PFS) in Patients with Short Tumor Telomere Length: Subgroup Analysis from a Randomized Phase II Study of the Telomerase Inhibitor Imetelstat as a Maintenance Therapy for Advanced NSCLC.
19. Baerlocher G, Oppliger Leibundgut E, Spitzer G, Ottmann O, Olatoyosi O, et al. (2013) Imetelstat: A Novel Approach with Robust Hematologic and Molecular Responses in a Phase II Study in Patients with Essential Thrombocythemia Who are Refractory or Intolerant to Prior Therapy. 2013 Congress of the European Hematology Association.
20. M Kozloff GWS, FM Benedetti, A Starr, JA Wallace, MJ Stuart, et al. (2010) Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 28: 15s.
21. Middleton G, Valle J, Wadsley J, Propper D, Coxon F, et al. (2013) A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol (suppl; abstr LBA4004).
22. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, et al. (2006) Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55: 1553-1564.